Reverie will use its technology platform to perform virtual screening, hit-to-lead generation, and lead optimization of several kinase inhibitor discovery programs in collaboration with Roche and Genentech scientists. Reverie will use its scalable infrastructure to train machine-learning models for kinase potency, kinome selectivity, and metabolism and toxicity properties to generate millions of novel chemical structures to evaluate.

Under the agreement, Reverie will receive an upfront payment of an undisclosed amount and will be eligible for preclinical, clinical, and regulatory milestone payments, as well as tiered royalties on Roche's sale of drug candidates produced from the collaboration.

Machine learning helps identify antimicrobial-resistant bacteria
A new graphical user interface-driven, machine learning-based approach has successfully identified antimicrobial resistance genes for gram-positive and...

From DNA to precision medicine, researchers discuss breakthroughs in cancer research
From the use of novel technologies such as machine learning and CRISPR, to gaining a deeper understanding of the genetic and molecular drivers of cancer,...